LAUSR

Abstract. Significance: Fluorescence guidance in cancer surgery (FGS) using molecular-targeted contrast agents is accelerating, yet the influence of individual patients’ physiology on the optimal time to perform surgery post-agent-injection is not fully understood. Aim: Develop a mathematical framework and analytical expressions to estimate patient-specific time-to-maximum contrast after imaging agent administration for single- and paired-agent (coadministration of targeted and control agents) protocols. Approach: The framework was validated in mouse subcutaneous xenograft studies for three classes of imaging agents: peptide, antibody mimetic, and antibody. Analytical expressions estimating time-to-maximum-tumor-discrimination potential were evaluated over a range of parameters using the validated framework for human cancer parameters. Results: Correlations were observed between simulations and matched experiments and metrics of tumor discrimination potential (p  <  0.05). Based on human cancer physiology, times-to-maximum contrast for peptide and antibody mimetic agents were <200  min, >15  h for antibodies, on average. The analytical estimates of time-to-maximum tumor discrimination performance exhibited errors of <10  %   on average, whereas patient-to-patient variance is expected to be greater than 100%. Conclusion: We demonstrated that analytical estimates of time-to-maximum contrast in FGS carried out patient-to-patient can outperform the population average time-to-maximum contrast used currently in clinical trials. Such estimates can be made with preoperative DCE-MRI (or similar) and knowledge of the targeted agent’s binding affinity.